Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Recruiting 3Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 49Immunoglobulin Light-chain Amyloidosis 6Recurrence 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Neoplasm, Residual 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Myelodysplastic Syndromes 2Lymphoma 2Smoldering Multiple Myeloma 1Proteostasis Deficiencies 1Primary Myelofibrosis 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Peripheral 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1Autoimmune Diseases of the Nervous System 1Anti-N-Methyl-D-Aspartate Receptor Encephalitis 1Anemia, Aplastic 1Amyloidosis 1Acute Kidney Injury 1

Interventions

Cyclophosphamide 7venetoclax 6Azacitidine 6fludarabine 5Cytarabine 4Blood Specimen Collection 4daratumumab 3Lenalidomide 3Daunorubicin 3tislelizumab 2fludarabine phosphate 2Rituximab 2Liquid Biopsy 2Idarubicin 2Gemtuzumab 2Capecitabine 2Busulfan 2trastuzumab deruxtecan 1thymoglobulin 1tetrathiomolybdate 1talquetamab 1tagraxofusp 1sugemalimab 1sacituzumab govitecan 1relugolix 1pembrolizumab 1pegaspargase 1palbociclib 1obinutuzumab 1ivosidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Neoplasm, Residual × daratumumab × Clear all
NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

University of Alabama at Birmingham

Phase 2 Recruiting
40 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT07021677 2025-06-15

DARA_T_ALL

Tata Memorial Centre

Phase 2 Recruiting
18 enrolled
LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06697483 2024-11-25

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Peking University People's Hospital

Phase NA Recruiting
100 enrolled
Plasma cell

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡